<DOC>
	<DOCNO>NCT02211066</DOCNO>
	<brief_summary>The study single-centre , randomize , active control , open label clinical trial . The primary hypothesis ticagrelor show superiority clopidogrel immediately CTO-PCI ( chronic total occlusion - percutaneous coronary intervention )</brief_summary>
	<brief_title>TIcaGrEloR ABSORB Bioresorbable Vascular Scaffold Implantation Recovery Vascular Function After Successful Chronic Total Occlusion Recanalization</brief_title>
	<detailed_description>The hypothesis test first randomization . Both antiplatelet therapy use arm approve dos approve duration therapy 1-year . The secondary hypothesis test role ticagrelor/clopidogrel alone together ABSORB BVS implantation recovery vascular function long-term . This hypothesis test second randomization . The angiographic follow-up schedule 1 3-year follow-up order test secondary hypothesis either moment end antiplatelet therapy moment scaffold bioresorption .</detailed_description>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Patients sex , old 18 year old . Written inform consent obtain . Patients stable angina pectoris ( Canadian Cardiovascular Society ( CCS ) Class 1 , 2 , 3 4 ) patient document silent ischemia stress test last year . Patients eligible coronary revascularization coronary chronic total occlusion , angiographically document previous coronary angiography last year . Women pregnant woman childbearing potential use adequate contraception . Known allergy aspirin , clopidogrel bisulfate ( Plavix Â® ) , ticagrelor ( BriliqueTM ) heparin , sensitivity contrast medium , adequately premedicated . Participation study . Life expectancy less one year factor make clinical and/or angiographic followup difficult . Planned cardiac surgery major noncardiac surgery . The subject history bleed diathesis coagulopathy . The subject suffer disable stroke within past year . Known major hematologic , neoplastic , metabolic , gastrointestinal endocrine dysfunction , , judgment Investigator , may affect patient 's ability complete study . History malignancy , except patient diseasefree &gt; 5 year whose malignancy basal squamous cell skin carcinoma . Inability provide inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>